IL-36 receptor antagonistic antibodies inhibit inflammatory responses in preclinical models of psoriasiform dermatitis.
Su Z, Paulsboe S, Wetter J, Salte K, Kannan A, Mathew S, Horowitz A, Gerstein C, Namovic M, Todorović V, Seagal J, Edelmayer RM, Viner M, Rinaldi L, Zhou L, Leys L, Huang S, Wang L, Sadhukhan R, Honore P, McGaraughty S, Scott VE.
Su Z, et al. Among authors: viner m.
Exp Dermatol. 2019 Feb;28(2):113-120. doi: 10.1111/exd.13841. Epub 2018 Dec 21.
Exp Dermatol. 2019.
PMID: 30417427